| Year(s) Study Open |
Name of Study |
Sponsor
|
Local Principal/Co-
Investigators
|
Subject Accrual
|
|
Cohort Studies |
|
|
|
| 1992-present |
Women & Infant Transmission Study (WITS) |
NICHD |
S. Landesman
E. Handelsman |
296 |
| 1994-present |
Women's Interagency HIV Study (WIHS) |
NIAID/
NIDA/NCI |
H. Minkoff /
J. DeHovitz |
609 |
| 1996-1999 |
Determinants of HIV Testing & Perinatal ZDV Use |
CDC |
J. DeHovitz /
H. Minkoff |
684 |
| 2001-2003 |
HIV Practice Cooperative- "Observation Study to Assess Patient Attitudes About Antiretroviral Medication Changes" |
Merck |
J. DeHovitz |
60 |
| 2002-present |
HIV Treatment Adherence Demonstration Project |
NYS AIDS Institute |
T. Wilson |
60 |
| 2002 - present |
Observational Study of Treated and Untreated Acute and Early HIV-1 Infection |
AIEDRP |
M. Markowitz
|
1 |
| 2002- present |
A Large Simple Trial Comparing Two Strategies for Management of Antiretroviral Therapy |
NIAIDS/DAIDS |
J. DeHovitz
|
20 |
|
Diagnostic Studies |
|
|
|
| 1998-1999 |
Identification of HIV-1 urine antibody positive, HIV-1 seronegative individuals |
Calypte |
J. DeHovitz |
149 |
|
Clinical Treatment Trials |
|
|
|
| 1991-present |
Pediatric AIDS Clinical Trials Unit (KCHC) |
NICHD/NIAID |
H. Mendez/
E. Handelsman |
50 |
| 1998-2000 |
Phase IV study of Procrit given weekly |
Ortho Biotech |
S. Burney
|
14 |
| 1999-2001 |
Phase IIb study of Indinavir/Ritonavir twice a day plus3TC/d4T |
Merck |
J. DeHovitz
|
4 |
| 1999-2001 |
Phase IV study of gender differences in the pharmacokinetics of nelfinavir |
Agouron |
D. Singh/
R. Sharma/
J. Quale/
|
30 |
| 2000-2001 |
Expanded Access Program for ABT-378r (Kaletra) |
Abbott |
J. DeHovitz
|
8 |
| 2001 |
Expanded Access Program for Tenofovir DF (Viread) |
Gilead Sciences |
|
7 |
| 2001 - 2003 |
HIV Resistance Study I & II |
NYS Dept. of Health |
|
200 |
| 2002 |
Phase 2, Double-blind, Randomized, Placebo-controlled Study of Capravirine in Combination with Viracept |
Agouron/
Pfizer |
J. DeHovitz |
2 |
| 2002 |
Phase IIIB Atazanavir for HIV Infected Individuals: An Early Access Program |
BMS |
|
7 |
| 2002 |
VEST-QD: A Phace IV, Open-label, Randonmized, Multicenter Study Switching HIV-1 Infected Subjects to an Efavirenz Substitution Regimen |
BMS |
J. DeHovitz |
4 |
